Keyword: Astex Therapeutics
KRAS and its hope against cancer was one of the biggest talking points in 2019, and 2020 looks no different.
The DNA hypomethylating agent failed to beat the complete response or overall survival rates achieved in the control arm.
Neil Woodford has invested in the Big Pharma-backed Dementia Discovery Fund.
In this week's EuroBiotech Report, Cell Medica raises £60 million, Astex pockets Novartis milestone, Galapagos pens combination pact and more.
Astex Pharmaceuticals has pocketed a milestone payment from Novartis after the latter's cancer drug secured FDA approval.
Cancer Research UK has kicked off a Phase I/II trial to see if a DNA methyltransferase inhibitor can stop bladder cancers developing resistance to chemotherapy.